PIPAC :: Pressurized IntraPeritoneal Aerosol Chemotherapy - Cancer under Pressure.
<!Doctype html public ""-//w3c//dtd html 4.0 transitional//en""> <html><head> <meta content=""text/html; charset=iso-8859-1"" http-equiv=content-type> <meta name=generator content=""mshtml 8.00.6001.23543""><...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Weitere Verfasser: | |
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Berlin/Boston :
De Gruyter,
2014.
|
| Schlagworte: | |
| Online-Zugang: | DE-862 DE-863 |
| Zusammenfassung: | <!Doctype html public ""-//w3c//dtd html 4.0 transitional//en""> <html><head> <meta content=""text/html; charset=iso-8859-1"" http-equiv=content-type> <meta name=generator content=""mshtml 8.00.6001.23543""></head> <body> Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a novel approach for treating peritoneal carcinomatosis. First encouraging results have been obtained in human patients. </body></html> |
| Beschreibung: | 1 online resource (252 pages) |
| Bibliographie: | Includes bibliographical references at the end of each chapters and index. |
| ISBN: | 9783110366624 3110366622 9783110386363 3110386364 3110366614 9783110366617 |
Internformat
MARC
| LEADER | 00000cam a2200000Mi 4500 | ||
|---|---|---|---|
| 001 | ZDB-4-EBA-ocn898769643 | ||
| 003 | OCoLC | ||
| 005 | 20241004212047.0 | ||
| 006 | m o d | ||
| 007 | cr |n||||||||| | ||
| 008 | 141227s2014 mau ob 001 0 eng d | ||
| 010 | |a 2014025736 | ||
| 040 | |a EBLCP |b eng |e pn |c EBLCP |d OCLCQ |d E7B |d DEBBG |d IDEBK |d CCO |d OCLCO |d DEBSZ |d OCLCQ |d OCLCO |d AZK |d OCLCQ |d COCUF |d MOR |d PIFAG |d N$T |d ZCU |d OCLCQ |d MERUC |d OCLCQ |d DEGRU |d GWDNB |d U3W |d UIU |d D6H |d OCLCQ |d STF |d OCLCF |d ICG |d VT2 |d OCLCO |d OCLCQ |d WYU |d OCLCA |d TKN |d OCLCO |d LEAUB |d DKC |d OCLCO |d OCLCQ |d UKAHL |d UX1 |d OCLCQ |d OCLCA |d K6U |d OCLCA |d OCLCO |d OCLCQ |d OCLCO |d OCLCL | ||
| 016 | 7 | |a 1101864389 |2 DE-101 | |
| 016 | 7 | |a 1114101583 |2 DE-101 | |
| 019 | |a 910596279 |a 961609183 |a 962660203 |a 979912429 |a 992854780 |a 1055354381 |a 1066458776 |a 1081232722 |a 1148125797 |a 1228568064 | ||
| 020 | |a 9783110366624 |q (electronic bk.) | ||
| 020 | |a 3110366622 |q (electronic bk.) | ||
| 020 | |a 9783110386363 | ||
| 020 | |a 3110386364 | ||
| 020 | |a 3110366614 | ||
| 020 | |a 9783110366617 | ||
| 020 | |z 9783110366617 | ||
| 020 | |z 3110366614 | ||
| 020 | |z 3110345943 | ||
| 020 | |z 9783110345940 | ||
| 024 | 7 | |a 10.1515/9783110366617 |2 doi | |
| 024 | 3 | |a 9783110386363 | |
| 024 | 7 | |a urn:nbn:de:101:1-201605268680 |2 urn | |
| 024 | 3 | |a 9783110366617 | |
| 024 | 7 | |a urn:nbn:de:101:1-201609198266 |2 urn | |
| 035 | |a (OCoLC)898769643 |z (OCoLC)910596279 |z (OCoLC)961609183 |z (OCoLC)962660203 |z (OCoLC)979912429 |z (OCoLC)992854780 |z (OCoLC)1055354381 |z (OCoLC)1066458776 |z (OCoLC)1081232722 |z (OCoLC)1148125797 |z (OCoLC)1228568064 | ||
| 037 | |a 1692408 |b Proquest Ebook Central | ||
| 050 | 4 | |a RC271.C5 .P57 2014 | |
| 060 | 4 | |a QZ 267 | |
| 072 | 7 | |a HEA |x 039000 |2 bisacsh | |
| 072 | 7 | |a MED |x 014000 |2 bisacsh | |
| 072 | 7 | |a MED |x 022000 |2 bisacsh | |
| 072 | 7 | |a MED |x 112000 |2 bisacsh | |
| 072 | 7 | |a MED |x 045000 |2 bisacsh | |
| 082 | 7 | |a 616.994061 | |
| 084 | |a 610 |q DE-101 |2 sdnb | ||
| 049 | |a MAIN | ||
| 100 | 1 | |a Reymond, Marc A. | |
| 245 | 1 | 0 | |a PIPAC : |b Pressurized IntraPeritoneal Aerosol Chemotherapy - Cancer under Pressure. |
| 260 | |a Berlin/Boston : |b De Gruyter, |c 2014. | ||
| 300 | |a 1 online resource (252 pages) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 347 | |a text file |b PDF |2 rda | ||
| 588 | 0 | |a Print version record. | |
| 505 | 0 | |a Preface; Acknowledgments; 1 Introduction; 2 Peritoneal carcinomatosis: a neglected disease; 2.1 An unmet medical need; 2.2 Role of the physician in provision of care in advanced peritoneal cancer; 2.3 Palliative care in peritoneal carcinomatosis; 3 Normal and diseased peritoneum; 3.1 Ontology; 3.2 Anatomy; 3.2.1 Blood supply; 3.2.2 Lymphatics; 3.2.3 Lymphatic stomata; 3.2.4 Milky spots; 3.2.5 Greater omentum; 3.2.6 Peritoneal nerves; 3.3 Physiology of peritoneum; 3.3.1 Peritoneum-plasma barrier; 3.3.2 Intraperitoneal Hydrostatic Pressure; 3.4 Pathophysiology of peritoneal carcinomatosis. | |
| 505 | 8 | |a 3.4.1 Epithelial-mesenchymal transition3.4.2 Interstitial intratumoral fluid pressure; 3.4.3 Ascites; 3.4.4 Hormonal changes; 4 Diagnosis and staging of peritoneal carcinomatosis; 4.1 Diagnostic workup; 4.2 Imaging studies; 4.2.1 Computer tomography (CT scan); 4.2.2 Magnetic Resonance Imaging (MRI); 4.2.3 Ultrasound; 4.2.4 FDG-Positron emission tomography (PET); 4.3 Diagnostic laparoscopy; 4.3.1 Peritoneal Cancer Index; 4.4 Peritoneal or pleural cytology; 4.4.1 Gastric cancer; 4.4.2 Ovarian cancer; 4.4.3 Colorectal cancer; 5 Therapy of peritoneal carcinomatosis. | |
| 505 | 8 | |a 5.1 Systemic palliative chemotherapy5.2 Intraperitoneal chemotherapy; 5.3 Drug uptake into tumoral tissue; 5.3.1 Diffusion; 5.3.2 Convection; 5.4 Effect of peritonectomy on drug clearance; 5.5 Influence of intraperitoneal drug concentration; 5.6 Tissue penetration of various drugs; 5.6.1 Doxorubicin (see also page 199); 5.6.2 Cisplatinum (see also page 198); 5.6.3 Oxaliplatinum; 5.6.4 Taxanes (Paclitaxel, Docetaxel); 5.7 Perioperative intraperitoneal chemotherapy; 5.7.1 CHPP; 5.7.2 NIPS; 5.7.3 EIPL; 5.7.4 EPIC; 5.8 Intraperitoneal chemotherapy for ascites. | |
| 505 | 8 | |a 5.9 Limitations of intraperitoneal chemotherapy5.9.1 Poor drug penetration; 5.9.2 Poor surface exposition; 5.9.3 Local toxicity; 5.9.4 Peritoneal sclerosis; 5.10 Intraperitoneal immunotherapy; 5.10.1 Catumaxomab; 5.10.2 Bevacizumab; 5.10.3 Immunoradiotherapy; 5.11 Intraperitoneal cytolytic virotherapy; 5.12 Nanodrugs; 5.13 Combined CRS with HIPEC; 5.13.1 Cytoreductive surgery (CRS); 5.13.2 Hyperthermic IntraPEritoneal Chemotherapy (HIPEC); 5.13.3 Colorectal cancer; 5.13.4 Ovarian Cancer; 5.13.5 Gastric Cancer; 5.13.6 Learning curve and expertise; 5.13.7 Evidence of cost effectiveness. | |
| 505 | 8 | |a 5.13.8 Safety5.13.9 Indications for CRS and HIPEC; 6 Assessing tumor response in peritoneal carcinomatosis; 6.1 Natural history of peritoneal carcinomatosis; 6.2 RECIST criteria; 6.2.1 RECIST criteria in peritoneal carcinomatosis; 6.3 Laparoscopy in peritoneal carcinomatosis; 6.4 Histology for determining tumor response; 6.5 Tumor markers for determining tumor response; 6.5.1 Gastric cancer; 6.5.2 Ovarian cancer; 6.5.3 Colorectal cancer; 6.6 Determining clinical benefit rate in peritoneal carcinomatosis; 7 Principle of therapeutic capnoperitoneum; 7.1 Material and methods. | |
| 505 | 8 | |a 7.1.1 Design of the prototype. | |
| 520 | |a <!Doctype html public ""-//w3c//dtd html 4.0 transitional//en""> <html><head> <meta content=""text/html; charset=iso-8859-1"" http-equiv=content-type> <meta name=generator content=""mshtml 8.00.6001.23543""></head> <body> Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a novel approach for treating peritoneal carcinomatosis. First encouraging results have been obtained in human patients. </body></html> | ||
| 504 | |a Includes bibliographical references at the end of each chapters and index. | ||
| 546 | |a In English. | ||
| 650 | 0 | |a Antineoplastic agents. |0 http://id.loc.gov/authorities/subjects/sh85005714 | |
| 650 | 0 | |a Aerosol. | |
| 650 | 1 | 2 | |a Antineoplastic Combined Chemotherapy Protocols |
| 650 | 1 | 2 | |a Peritoneal Neoplasms |x drug therapy |
| 650 | 2 | 2 | |a Aerosols |x therapeutic use |
| 650 | 2 | 2 | |a Carcinoma |x drug therapy |
| 650 | 6 | |a Anticancéreux. | |
| 650 | 7 | |a HEALTH & FITNESS |x Diseases |x General. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Clinical Medicine. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Diseases. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Evidence-Based Medicine. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Internal Medicine. |2 bisacsh | |
| 650 | 7 | |a Antineoplastic agents |2 fast | |
| 650 | 7 | |a Peritonealkarzinose |2 gnd |0 http://d-nb.info/gnd/4411985-9 | |
| 650 | 7 | |a Pressurized Intraperitoneal Aerosol Chemotherapy |2 gnd |0 http://d-nb.info/gnd/1067996001 | |
| 655 | 7 | |a Aufsatzsammlung. |2 gnd | |
| 700 | 1 | |a Solass, Wiebke. | |
| 758 | |i has work: |a PIPAC (Text) |1 https://id.oclc.org/worldcat/entity/E39PCG4ggFDFG6g47WxjRKy9j3 |4 https://id.oclc.org/worldcat/ontology/hasWork | ||
| 776 | 0 | 8 | |i Print version: |a Reymond, Marc A. |t PIPAC : Pressurized IntraPeritoneal Aerosol Chemotherapy - Cancer under Pressure. |d Berlin/Boston : De Gruyter, ©2014 |z 9783110345940 |
| 966 | 4 | 0 | |l DE-862 |p ZDB-4-EBA |q FWS_PDA_EBA |u https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=887007 |3 Volltext |
| 966 | 4 | 0 | |l DE-863 |p ZDB-4-EBA |q FWS_PDA_EBA |u https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=887007 |3 Volltext |
| 938 | |a Askews and Holts Library Services |b ASKH |n AH26829312 | ||
| 938 | |a Askews and Holts Library Services |b ASKH |n AH26746827 | ||
| 938 | |a De Gruyter |b DEGR |n 9783110366617 | ||
| 938 | |a EBL - Ebook Library |b EBLB |n EBL1692408 | ||
| 938 | |a ebrary |b EBRY |n ebr11014008 | ||
| 938 | |a EBSCOhost |b EBSC |n 887007 | ||
| 938 | |a ProQuest MyiLibrary Digital eBook Collection |b IDEB |n cis28427326 | ||
| 994 | |a 92 |b GEBAY | ||
| 912 | |a ZDB-4-EBA | ||
| 049 | |a DE-862 | ||
| 049 | |a DE-863 | ||
Datensatz im Suchindex
| DE-BY-FWS_katkey | ZDB-4-EBA-ocn898769643 |
|---|---|
| _version_ | 1826942068801404928 |
| adam_text | |
| any_adam_object | |
| author | Reymond, Marc A. |
| author2 | Solass, Wiebke |
| author2_role | |
| author2_variant | w s ws |
| author_facet | Reymond, Marc A. Solass, Wiebke |
| author_role | |
| author_sort | Reymond, Marc A. |
| author_variant | m a r ma mar |
| building | Verbundindex |
| bvnumber | localFWS |
| callnumber-first | R - Medicine |
| callnumber-label | RC271 |
| callnumber-raw | RC271.C5 .P57 2014 |
| callnumber-search | RC271.C5 .P57 2014 |
| callnumber-sort | RC 3271 C5 P57 42014 |
| callnumber-subject | RC - Internal Medicine |
| collection | ZDB-4-EBA |
| contents | Preface; Acknowledgments; 1 Introduction; 2 Peritoneal carcinomatosis: a neglected disease; 2.1 An unmet medical need; 2.2 Role of the physician in provision of care in advanced peritoneal cancer; 2.3 Palliative care in peritoneal carcinomatosis; 3 Normal and diseased peritoneum; 3.1 Ontology; 3.2 Anatomy; 3.2.1 Blood supply; 3.2.2 Lymphatics; 3.2.3 Lymphatic stomata; 3.2.4 Milky spots; 3.2.5 Greater omentum; 3.2.6 Peritoneal nerves; 3.3 Physiology of peritoneum; 3.3.1 Peritoneum-plasma barrier; 3.3.2 Intraperitoneal Hydrostatic Pressure; 3.4 Pathophysiology of peritoneal carcinomatosis. 3.4.1 Epithelial-mesenchymal transition3.4.2 Interstitial intratumoral fluid pressure; 3.4.3 Ascites; 3.4.4 Hormonal changes; 4 Diagnosis and staging of peritoneal carcinomatosis; 4.1 Diagnostic workup; 4.2 Imaging studies; 4.2.1 Computer tomography (CT scan); 4.2.2 Magnetic Resonance Imaging (MRI); 4.2.3 Ultrasound; 4.2.4 FDG-Positron emission tomography (PET); 4.3 Diagnostic laparoscopy; 4.3.1 Peritoneal Cancer Index; 4.4 Peritoneal or pleural cytology; 4.4.1 Gastric cancer; 4.4.2 Ovarian cancer; 4.4.3 Colorectal cancer; 5 Therapy of peritoneal carcinomatosis. 5.1 Systemic palliative chemotherapy5.2 Intraperitoneal chemotherapy; 5.3 Drug uptake into tumoral tissue; 5.3.1 Diffusion; 5.3.2 Convection; 5.4 Effect of peritonectomy on drug clearance; 5.5 Influence of intraperitoneal drug concentration; 5.6 Tissue penetration of various drugs; 5.6.1 Doxorubicin (see also page 199); 5.6.2 Cisplatinum (see also page 198); 5.6.3 Oxaliplatinum; 5.6.4 Taxanes (Paclitaxel, Docetaxel); 5.7 Perioperative intraperitoneal chemotherapy; 5.7.1 CHPP; 5.7.2 NIPS; 5.7.3 EIPL; 5.7.4 EPIC; 5.8 Intraperitoneal chemotherapy for ascites. 5.9 Limitations of intraperitoneal chemotherapy5.9.1 Poor drug penetration; 5.9.2 Poor surface exposition; 5.9.3 Local toxicity; 5.9.4 Peritoneal sclerosis; 5.10 Intraperitoneal immunotherapy; 5.10.1 Catumaxomab; 5.10.2 Bevacizumab; 5.10.3 Immunoradiotherapy; 5.11 Intraperitoneal cytolytic virotherapy; 5.12 Nanodrugs; 5.13 Combined CRS with HIPEC; 5.13.1 Cytoreductive surgery (CRS); 5.13.2 Hyperthermic IntraPEritoneal Chemotherapy (HIPEC); 5.13.3 Colorectal cancer; 5.13.4 Ovarian Cancer; 5.13.5 Gastric Cancer; 5.13.6 Learning curve and expertise; 5.13.7 Evidence of cost effectiveness. 5.13.8 Safety5.13.9 Indications for CRS and HIPEC; 6 Assessing tumor response in peritoneal carcinomatosis; 6.1 Natural history of peritoneal carcinomatosis; 6.2 RECIST criteria; 6.2.1 RECIST criteria in peritoneal carcinomatosis; 6.3 Laparoscopy in peritoneal carcinomatosis; 6.4 Histology for determining tumor response; 6.5 Tumor markers for determining tumor response; 6.5.1 Gastric cancer; 6.5.2 Ovarian cancer; 6.5.3 Colorectal cancer; 6.6 Determining clinical benefit rate in peritoneal carcinomatosis; 7 Principle of therapeutic capnoperitoneum; 7.1 Material and methods. 7.1.1 Design of the prototype. |
| ctrlnum | (OCoLC)898769643 |
| dewey-full | 616.994061 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.994061 |
| dewey-search | 616.994061 |
| dewey-sort | 3616.994061 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>07672cam a2201033Mi 4500</leader><controlfield tag="001">ZDB-4-EBA-ocn898769643</controlfield><controlfield tag="003">OCoLC</controlfield><controlfield tag="005">20241004212047.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr |n|||||||||</controlfield><controlfield tag="008">141227s2014 mau ob 001 0 eng d</controlfield><datafield tag="010" ind1=" " ind2=" "><subfield code="a"> 2014025736</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">EBLCP</subfield><subfield code="b">eng</subfield><subfield code="e">pn</subfield><subfield code="c">EBLCP</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">E7B</subfield><subfield code="d">DEBBG</subfield><subfield code="d">IDEBK</subfield><subfield code="d">CCO</subfield><subfield code="d">OCLCO</subfield><subfield code="d">DEBSZ</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCO</subfield><subfield code="d">AZK</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">COCUF</subfield><subfield code="d">MOR</subfield><subfield code="d">PIFAG</subfield><subfield code="d">N$T</subfield><subfield code="d">ZCU</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">MERUC</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">DEGRU</subfield><subfield code="d">GWDNB</subfield><subfield code="d">U3W</subfield><subfield code="d">UIU</subfield><subfield code="d">D6H</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">STF</subfield><subfield code="d">OCLCF</subfield><subfield code="d">ICG</subfield><subfield code="d">VT2</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">WYU</subfield><subfield code="d">OCLCA</subfield><subfield code="d">TKN</subfield><subfield code="d">OCLCO</subfield><subfield code="d">LEAUB</subfield><subfield code="d">DKC</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">UKAHL</subfield><subfield code="d">UX1</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCA</subfield><subfield code="d">K6U</subfield><subfield code="d">OCLCA</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCL</subfield></datafield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">1101864389</subfield><subfield code="2">DE-101</subfield></datafield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">1114101583</subfield><subfield code="2">DE-101</subfield></datafield><datafield tag="019" ind1=" " ind2=" "><subfield code="a">910596279</subfield><subfield code="a">961609183</subfield><subfield code="a">962660203</subfield><subfield code="a">979912429</subfield><subfield code="a">992854780</subfield><subfield code="a">1055354381</subfield><subfield code="a">1066458776</subfield><subfield code="a">1081232722</subfield><subfield code="a">1148125797</subfield><subfield code="a">1228568064</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783110366624</subfield><subfield code="q">(electronic bk.)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">3110366622</subfield><subfield code="q">(electronic bk.)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783110386363</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">3110386364</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">3110366614</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783110366617</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">9783110366617</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">3110366614</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">3110345943</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">9783110345940</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1515/9783110366617</subfield><subfield code="2">doi</subfield></datafield><datafield tag="024" ind1="3" ind2=" "><subfield code="a">9783110386363</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">urn:nbn:de:101:1-201605268680</subfield><subfield code="2">urn</subfield></datafield><datafield tag="024" ind1="3" ind2=" "><subfield code="a">9783110366617</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">urn:nbn:de:101:1-201609198266</subfield><subfield code="2">urn</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)898769643</subfield><subfield code="z">(OCoLC)910596279</subfield><subfield code="z">(OCoLC)961609183</subfield><subfield code="z">(OCoLC)962660203</subfield><subfield code="z">(OCoLC)979912429</subfield><subfield code="z">(OCoLC)992854780</subfield><subfield code="z">(OCoLC)1055354381</subfield><subfield code="z">(OCoLC)1066458776</subfield><subfield code="z">(OCoLC)1081232722</subfield><subfield code="z">(OCoLC)1148125797</subfield><subfield code="z">(OCoLC)1228568064</subfield></datafield><datafield tag="037" ind1=" " ind2=" "><subfield code="a">1692408</subfield><subfield code="b">Proquest Ebook Central</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">RC271.C5 .P57 2014</subfield></datafield><datafield tag="060" ind1=" " ind2="4"><subfield code="a">QZ 267</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">HEA</subfield><subfield code="x">039000</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">MED</subfield><subfield code="x">014000</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">MED</subfield><subfield code="x">022000</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">MED</subfield><subfield code="x">112000</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">MED</subfield><subfield code="x">045000</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="082" ind1="7" ind2=" "><subfield code="a">616.994061</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">610</subfield><subfield code="q">DE-101</subfield><subfield code="2">sdnb</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">MAIN</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Reymond, Marc A.</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">PIPAC :</subfield><subfield code="b">Pressurized IntraPeritoneal Aerosol Chemotherapy - Cancer under Pressure.</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="a">Berlin/Boston :</subfield><subfield code="b">De Gruyter,</subfield><subfield code="c">2014.</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (252 pages)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="347" ind1=" " ind2=" "><subfield code="a">text file</subfield><subfield code="b">PDF</subfield><subfield code="2">rda</subfield></datafield><datafield tag="588" ind1="0" ind2=" "><subfield code="a">Print version record.</subfield></datafield><datafield tag="505" ind1="0" ind2=" "><subfield code="a">Preface; Acknowledgments; 1 Introduction; 2 Peritoneal carcinomatosis: a neglected disease; 2.1 An unmet medical need; 2.2 Role of the physician in provision of care in advanced peritoneal cancer; 2.3 Palliative care in peritoneal carcinomatosis; 3 Normal and diseased peritoneum; 3.1 Ontology; 3.2 Anatomy; 3.2.1 Blood supply; 3.2.2 Lymphatics; 3.2.3 Lymphatic stomata; 3.2.4 Milky spots; 3.2.5 Greater omentum; 3.2.6 Peritoneal nerves; 3.3 Physiology of peritoneum; 3.3.1 Peritoneum-plasma barrier; 3.3.2 Intraperitoneal Hydrostatic Pressure; 3.4 Pathophysiology of peritoneal carcinomatosis.</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">3.4.1 Epithelial-mesenchymal transition3.4.2 Interstitial intratumoral fluid pressure; 3.4.3 Ascites; 3.4.4 Hormonal changes; 4 Diagnosis and staging of peritoneal carcinomatosis; 4.1 Diagnostic workup; 4.2 Imaging studies; 4.2.1 Computer tomography (CT scan); 4.2.2 Magnetic Resonance Imaging (MRI); 4.2.3 Ultrasound; 4.2.4 FDG-Positron emission tomography (PET); 4.3 Diagnostic laparoscopy; 4.3.1 Peritoneal Cancer Index; 4.4 Peritoneal or pleural cytology; 4.4.1 Gastric cancer; 4.4.2 Ovarian cancer; 4.4.3 Colorectal cancer; 5 Therapy of peritoneal carcinomatosis.</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">5.1 Systemic palliative chemotherapy5.2 Intraperitoneal chemotherapy; 5.3 Drug uptake into tumoral tissue; 5.3.1 Diffusion; 5.3.2 Convection; 5.4 Effect of peritonectomy on drug clearance; 5.5 Influence of intraperitoneal drug concentration; 5.6 Tissue penetration of various drugs; 5.6.1 Doxorubicin (see also page 199); 5.6.2 Cisplatinum (see also page 198); 5.6.3 Oxaliplatinum; 5.6.4 Taxanes (Paclitaxel, Docetaxel); 5.7 Perioperative intraperitoneal chemotherapy; 5.7.1 CHPP; 5.7.2 NIPS; 5.7.3 EIPL; 5.7.4 EPIC; 5.8 Intraperitoneal chemotherapy for ascites.</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">5.9 Limitations of intraperitoneal chemotherapy5.9.1 Poor drug penetration; 5.9.2 Poor surface exposition; 5.9.3 Local toxicity; 5.9.4 Peritoneal sclerosis; 5.10 Intraperitoneal immunotherapy; 5.10.1 Catumaxomab; 5.10.2 Bevacizumab; 5.10.3 Immunoradiotherapy; 5.11 Intraperitoneal cytolytic virotherapy; 5.12 Nanodrugs; 5.13 Combined CRS with HIPEC; 5.13.1 Cytoreductive surgery (CRS); 5.13.2 Hyperthermic IntraPEritoneal Chemotherapy (HIPEC); 5.13.3 Colorectal cancer; 5.13.4 Ovarian Cancer; 5.13.5 Gastric Cancer; 5.13.6 Learning curve and expertise; 5.13.7 Evidence of cost effectiveness.</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">5.13.8 Safety5.13.9 Indications for CRS and HIPEC; 6 Assessing tumor response in peritoneal carcinomatosis; 6.1 Natural history of peritoneal carcinomatosis; 6.2 RECIST criteria; 6.2.1 RECIST criteria in peritoneal carcinomatosis; 6.3 Laparoscopy in peritoneal carcinomatosis; 6.4 Histology for determining tumor response; 6.5 Tumor markers for determining tumor response; 6.5.1 Gastric cancer; 6.5.2 Ovarian cancer; 6.5.3 Colorectal cancer; 6.6 Determining clinical benefit rate in peritoneal carcinomatosis; 7 Principle of therapeutic capnoperitoneum; 7.1 Material and methods.</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">7.1.1 Design of the prototype.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a"><!Doctype html public ""-//w3c//dtd html 4.0 transitional//en""> <html><head> <meta content=""text/html; charset=iso-8859-1"" http-equiv=content-type> <meta name=generator content=""mshtml 8.00.6001.23543""></head> <body> Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a novel approach for treating peritoneal carcinomatosis. First encouraging results have been obtained in human patients. </body></html></subfield></datafield><datafield tag="504" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references at the end of each chapters and index.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">In English.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Antineoplastic agents.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85005714</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Aerosol.</subfield></datafield><datafield tag="650" ind1="1" ind2="2"><subfield code="a">Antineoplastic Combined Chemotherapy Protocols</subfield></datafield><datafield tag="650" ind1="1" ind2="2"><subfield code="a">Peritoneal Neoplasms</subfield><subfield code="x">drug therapy</subfield></datafield><datafield tag="650" ind1="2" ind2="2"><subfield code="a">Aerosols</subfield><subfield code="x">therapeutic use</subfield></datafield><datafield tag="650" ind1="2" ind2="2"><subfield code="a">Carcinoma</subfield><subfield code="x">drug therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Anticancéreux.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">HEALTH & FITNESS</subfield><subfield code="x">Diseases</subfield><subfield code="x">General.</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL</subfield><subfield code="x">Clinical Medicine.</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL</subfield><subfield code="x">Diseases.</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL</subfield><subfield code="x">Evidence-Based Medicine.</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL</subfield><subfield code="x">Internal Medicine.</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Antineoplastic agents</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Peritonealkarzinose</subfield><subfield code="2">gnd</subfield><subfield code="0">http://d-nb.info/gnd/4411985-9</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pressurized Intraperitoneal Aerosol Chemotherapy</subfield><subfield code="2">gnd</subfield><subfield code="0">http://d-nb.info/gnd/1067996001</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="a">Aufsatzsammlung.</subfield><subfield code="2">gnd</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Solass, Wiebke.</subfield></datafield><datafield tag="758" ind1=" " ind2=" "><subfield code="i">has work:</subfield><subfield code="a">PIPAC (Text)</subfield><subfield code="1">https://id.oclc.org/worldcat/entity/E39PCG4ggFDFG6g47WxjRKy9j3</subfield><subfield code="4">https://id.oclc.org/worldcat/ontology/hasWork</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Print version:</subfield><subfield code="a">Reymond, Marc A.</subfield><subfield code="t">PIPAC : Pressurized IntraPeritoneal Aerosol Chemotherapy - Cancer under Pressure.</subfield><subfield code="d">Berlin/Boston : De Gruyter, ©2014</subfield><subfield code="z">9783110345940</subfield></datafield><datafield tag="966" ind1="4" ind2="0"><subfield code="l">DE-862</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FWS_PDA_EBA</subfield><subfield code="u">https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=887007</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="4" ind2="0"><subfield code="l">DE-863</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FWS_PDA_EBA</subfield><subfield code="u">https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=887007</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">Askews and Holts Library Services</subfield><subfield code="b">ASKH</subfield><subfield code="n">AH26829312</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">Askews and Holts Library Services</subfield><subfield code="b">ASKH</subfield><subfield code="n">AH26746827</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">De Gruyter</subfield><subfield code="b">DEGR</subfield><subfield code="n">9783110366617</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">EBL - Ebook Library</subfield><subfield code="b">EBLB</subfield><subfield code="n">EBL1692408</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">ebrary</subfield><subfield code="b">EBRY</subfield><subfield code="n">ebr11014008</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">EBSCOhost</subfield><subfield code="b">EBSC</subfield><subfield code="n">887007</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">ProQuest MyiLibrary Digital eBook Collection</subfield><subfield code="b">IDEB</subfield><subfield code="n">cis28427326</subfield></datafield><datafield tag="994" ind1=" " ind2=" "><subfield code="a">92</subfield><subfield code="b">GEBAY</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-EBA</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-862</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-863</subfield></datafield></record></collection> |
| genre | Aufsatzsammlung. gnd |
| genre_facet | Aufsatzsammlung. |
| id | ZDB-4-EBA-ocn898769643 |
| illustrated | Not Illustrated |
| indexdate | 2025-03-18T14:22:08Z |
| institution | BVB |
| isbn | 9783110366624 3110366622 9783110386363 3110386364 3110366614 9783110366617 |
| language | English |
| lccn | 2014025736 |
| oclc_num | 898769643 |
| open_access_boolean | |
| owner | MAIN DE-862 DE-BY-FWS DE-863 DE-BY-FWS |
| owner_facet | MAIN DE-862 DE-BY-FWS DE-863 DE-BY-FWS |
| physical | 1 online resource (252 pages) |
| psigel | ZDB-4-EBA FWS_PDA_EBA ZDB-4-EBA |
| publishDate | 2014 |
| publishDateSearch | 2014 |
| publishDateSort | 2014 |
| publisher | De Gruyter, |
| record_format | marc |
| spelling | Reymond, Marc A. PIPAC : Pressurized IntraPeritoneal Aerosol Chemotherapy - Cancer under Pressure. Berlin/Boston : De Gruyter, 2014. 1 online resource (252 pages) text txt rdacontent computer c rdamedia online resource cr rdacarrier text file PDF rda Print version record. Preface; Acknowledgments; 1 Introduction; 2 Peritoneal carcinomatosis: a neglected disease; 2.1 An unmet medical need; 2.2 Role of the physician in provision of care in advanced peritoneal cancer; 2.3 Palliative care in peritoneal carcinomatosis; 3 Normal and diseased peritoneum; 3.1 Ontology; 3.2 Anatomy; 3.2.1 Blood supply; 3.2.2 Lymphatics; 3.2.3 Lymphatic stomata; 3.2.4 Milky spots; 3.2.5 Greater omentum; 3.2.6 Peritoneal nerves; 3.3 Physiology of peritoneum; 3.3.1 Peritoneum-plasma barrier; 3.3.2 Intraperitoneal Hydrostatic Pressure; 3.4 Pathophysiology of peritoneal carcinomatosis. 3.4.1 Epithelial-mesenchymal transition3.4.2 Interstitial intratumoral fluid pressure; 3.4.3 Ascites; 3.4.4 Hormonal changes; 4 Diagnosis and staging of peritoneal carcinomatosis; 4.1 Diagnostic workup; 4.2 Imaging studies; 4.2.1 Computer tomography (CT scan); 4.2.2 Magnetic Resonance Imaging (MRI); 4.2.3 Ultrasound; 4.2.4 FDG-Positron emission tomography (PET); 4.3 Diagnostic laparoscopy; 4.3.1 Peritoneal Cancer Index; 4.4 Peritoneal or pleural cytology; 4.4.1 Gastric cancer; 4.4.2 Ovarian cancer; 4.4.3 Colorectal cancer; 5 Therapy of peritoneal carcinomatosis. 5.1 Systemic palliative chemotherapy5.2 Intraperitoneal chemotherapy; 5.3 Drug uptake into tumoral tissue; 5.3.1 Diffusion; 5.3.2 Convection; 5.4 Effect of peritonectomy on drug clearance; 5.5 Influence of intraperitoneal drug concentration; 5.6 Tissue penetration of various drugs; 5.6.1 Doxorubicin (see also page 199); 5.6.2 Cisplatinum (see also page 198); 5.6.3 Oxaliplatinum; 5.6.4 Taxanes (Paclitaxel, Docetaxel); 5.7 Perioperative intraperitoneal chemotherapy; 5.7.1 CHPP; 5.7.2 NIPS; 5.7.3 EIPL; 5.7.4 EPIC; 5.8 Intraperitoneal chemotherapy for ascites. 5.9 Limitations of intraperitoneal chemotherapy5.9.1 Poor drug penetration; 5.9.2 Poor surface exposition; 5.9.3 Local toxicity; 5.9.4 Peritoneal sclerosis; 5.10 Intraperitoneal immunotherapy; 5.10.1 Catumaxomab; 5.10.2 Bevacizumab; 5.10.3 Immunoradiotherapy; 5.11 Intraperitoneal cytolytic virotherapy; 5.12 Nanodrugs; 5.13 Combined CRS with HIPEC; 5.13.1 Cytoreductive surgery (CRS); 5.13.2 Hyperthermic IntraPEritoneal Chemotherapy (HIPEC); 5.13.3 Colorectal cancer; 5.13.4 Ovarian Cancer; 5.13.5 Gastric Cancer; 5.13.6 Learning curve and expertise; 5.13.7 Evidence of cost effectiveness. 5.13.8 Safety5.13.9 Indications for CRS and HIPEC; 6 Assessing tumor response in peritoneal carcinomatosis; 6.1 Natural history of peritoneal carcinomatosis; 6.2 RECIST criteria; 6.2.1 RECIST criteria in peritoneal carcinomatosis; 6.3 Laparoscopy in peritoneal carcinomatosis; 6.4 Histology for determining tumor response; 6.5 Tumor markers for determining tumor response; 6.5.1 Gastric cancer; 6.5.2 Ovarian cancer; 6.5.3 Colorectal cancer; 6.6 Determining clinical benefit rate in peritoneal carcinomatosis; 7 Principle of therapeutic capnoperitoneum; 7.1 Material and methods. 7.1.1 Design of the prototype. <!Doctype html public ""-//w3c//dtd html 4.0 transitional//en""> <html><head> <meta content=""text/html; charset=iso-8859-1"" http-equiv=content-type> <meta name=generator content=""mshtml 8.00.6001.23543""></head> <body> Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a novel approach for treating peritoneal carcinomatosis. First encouraging results have been obtained in human patients. </body></html> Includes bibliographical references at the end of each chapters and index. In English. Antineoplastic agents. http://id.loc.gov/authorities/subjects/sh85005714 Aerosol. Antineoplastic Combined Chemotherapy Protocols Peritoneal Neoplasms drug therapy Aerosols therapeutic use Carcinoma drug therapy Anticancéreux. HEALTH & FITNESS Diseases General. bisacsh MEDICAL Clinical Medicine. bisacsh MEDICAL Diseases. bisacsh MEDICAL Evidence-Based Medicine. bisacsh MEDICAL Internal Medicine. bisacsh Antineoplastic agents fast Peritonealkarzinose gnd http://d-nb.info/gnd/4411985-9 Pressurized Intraperitoneal Aerosol Chemotherapy gnd http://d-nb.info/gnd/1067996001 Aufsatzsammlung. gnd Solass, Wiebke. has work: PIPAC (Text) https://id.oclc.org/worldcat/entity/E39PCG4ggFDFG6g47WxjRKy9j3 https://id.oclc.org/worldcat/ontology/hasWork Print version: Reymond, Marc A. PIPAC : Pressurized IntraPeritoneal Aerosol Chemotherapy - Cancer under Pressure. Berlin/Boston : De Gruyter, ©2014 9783110345940 |
| spellingShingle | Reymond, Marc A. PIPAC : Pressurized IntraPeritoneal Aerosol Chemotherapy - Cancer under Pressure. Preface; Acknowledgments; 1 Introduction; 2 Peritoneal carcinomatosis: a neglected disease; 2.1 An unmet medical need; 2.2 Role of the physician in provision of care in advanced peritoneal cancer; 2.3 Palliative care in peritoneal carcinomatosis; 3 Normal and diseased peritoneum; 3.1 Ontology; 3.2 Anatomy; 3.2.1 Blood supply; 3.2.2 Lymphatics; 3.2.3 Lymphatic stomata; 3.2.4 Milky spots; 3.2.5 Greater omentum; 3.2.6 Peritoneal nerves; 3.3 Physiology of peritoneum; 3.3.1 Peritoneum-plasma barrier; 3.3.2 Intraperitoneal Hydrostatic Pressure; 3.4 Pathophysiology of peritoneal carcinomatosis. 3.4.1 Epithelial-mesenchymal transition3.4.2 Interstitial intratumoral fluid pressure; 3.4.3 Ascites; 3.4.4 Hormonal changes; 4 Diagnosis and staging of peritoneal carcinomatosis; 4.1 Diagnostic workup; 4.2 Imaging studies; 4.2.1 Computer tomography (CT scan); 4.2.2 Magnetic Resonance Imaging (MRI); 4.2.3 Ultrasound; 4.2.4 FDG-Positron emission tomography (PET); 4.3 Diagnostic laparoscopy; 4.3.1 Peritoneal Cancer Index; 4.4 Peritoneal or pleural cytology; 4.4.1 Gastric cancer; 4.4.2 Ovarian cancer; 4.4.3 Colorectal cancer; 5 Therapy of peritoneal carcinomatosis. 5.1 Systemic palliative chemotherapy5.2 Intraperitoneal chemotherapy; 5.3 Drug uptake into tumoral tissue; 5.3.1 Diffusion; 5.3.2 Convection; 5.4 Effect of peritonectomy on drug clearance; 5.5 Influence of intraperitoneal drug concentration; 5.6 Tissue penetration of various drugs; 5.6.1 Doxorubicin (see also page 199); 5.6.2 Cisplatinum (see also page 198); 5.6.3 Oxaliplatinum; 5.6.4 Taxanes (Paclitaxel, Docetaxel); 5.7 Perioperative intraperitoneal chemotherapy; 5.7.1 CHPP; 5.7.2 NIPS; 5.7.3 EIPL; 5.7.4 EPIC; 5.8 Intraperitoneal chemotherapy for ascites. 5.9 Limitations of intraperitoneal chemotherapy5.9.1 Poor drug penetration; 5.9.2 Poor surface exposition; 5.9.3 Local toxicity; 5.9.4 Peritoneal sclerosis; 5.10 Intraperitoneal immunotherapy; 5.10.1 Catumaxomab; 5.10.2 Bevacizumab; 5.10.3 Immunoradiotherapy; 5.11 Intraperitoneal cytolytic virotherapy; 5.12 Nanodrugs; 5.13 Combined CRS with HIPEC; 5.13.1 Cytoreductive surgery (CRS); 5.13.2 Hyperthermic IntraPEritoneal Chemotherapy (HIPEC); 5.13.3 Colorectal cancer; 5.13.4 Ovarian Cancer; 5.13.5 Gastric Cancer; 5.13.6 Learning curve and expertise; 5.13.7 Evidence of cost effectiveness. 5.13.8 Safety5.13.9 Indications for CRS and HIPEC; 6 Assessing tumor response in peritoneal carcinomatosis; 6.1 Natural history of peritoneal carcinomatosis; 6.2 RECIST criteria; 6.2.1 RECIST criteria in peritoneal carcinomatosis; 6.3 Laparoscopy in peritoneal carcinomatosis; 6.4 Histology for determining tumor response; 6.5 Tumor markers for determining tumor response; 6.5.1 Gastric cancer; 6.5.2 Ovarian cancer; 6.5.3 Colorectal cancer; 6.6 Determining clinical benefit rate in peritoneal carcinomatosis; 7 Principle of therapeutic capnoperitoneum; 7.1 Material and methods. 7.1.1 Design of the prototype. Antineoplastic agents. http://id.loc.gov/authorities/subjects/sh85005714 Aerosol. Antineoplastic Combined Chemotherapy Protocols Peritoneal Neoplasms drug therapy Aerosols therapeutic use Carcinoma drug therapy Anticancéreux. HEALTH & FITNESS Diseases General. bisacsh MEDICAL Clinical Medicine. bisacsh MEDICAL Diseases. bisacsh MEDICAL Evidence-Based Medicine. bisacsh MEDICAL Internal Medicine. bisacsh Antineoplastic agents fast Peritonealkarzinose gnd http://d-nb.info/gnd/4411985-9 Pressurized Intraperitoneal Aerosol Chemotherapy gnd http://d-nb.info/gnd/1067996001 |
| subject_GND | http://id.loc.gov/authorities/subjects/sh85005714 http://d-nb.info/gnd/4411985-9 http://d-nb.info/gnd/1067996001 |
| title | PIPAC : Pressurized IntraPeritoneal Aerosol Chemotherapy - Cancer under Pressure. |
| title_auth | PIPAC : Pressurized IntraPeritoneal Aerosol Chemotherapy - Cancer under Pressure. |
| title_exact_search | PIPAC : Pressurized IntraPeritoneal Aerosol Chemotherapy - Cancer under Pressure. |
| title_full | PIPAC : Pressurized IntraPeritoneal Aerosol Chemotherapy - Cancer under Pressure. |
| title_fullStr | PIPAC : Pressurized IntraPeritoneal Aerosol Chemotherapy - Cancer under Pressure. |
| title_full_unstemmed | PIPAC : Pressurized IntraPeritoneal Aerosol Chemotherapy - Cancer under Pressure. |
| title_short | PIPAC : |
| title_sort | pipac pressurized intraperitoneal aerosol chemotherapy cancer under pressure |
| title_sub | Pressurized IntraPeritoneal Aerosol Chemotherapy - Cancer under Pressure. |
| topic | Antineoplastic agents. http://id.loc.gov/authorities/subjects/sh85005714 Aerosol. Antineoplastic Combined Chemotherapy Protocols Peritoneal Neoplasms drug therapy Aerosols therapeutic use Carcinoma drug therapy Anticancéreux. HEALTH & FITNESS Diseases General. bisacsh MEDICAL Clinical Medicine. bisacsh MEDICAL Diseases. bisacsh MEDICAL Evidence-Based Medicine. bisacsh MEDICAL Internal Medicine. bisacsh Antineoplastic agents fast Peritonealkarzinose gnd http://d-nb.info/gnd/4411985-9 Pressurized Intraperitoneal Aerosol Chemotherapy gnd http://d-nb.info/gnd/1067996001 |
| topic_facet | Antineoplastic agents. Aerosol. Antineoplastic Combined Chemotherapy Protocols Peritoneal Neoplasms drug therapy Aerosols therapeutic use Carcinoma drug therapy Anticancéreux. HEALTH & FITNESS Diseases General. MEDICAL Clinical Medicine. MEDICAL Diseases. MEDICAL Evidence-Based Medicine. MEDICAL Internal Medicine. Antineoplastic agents Peritonealkarzinose Pressurized Intraperitoneal Aerosol Chemotherapy Aufsatzsammlung. |
| work_keys_str_mv | AT reymondmarca pipacpressurizedintraperitonealaerosolchemotherapycancerunderpressure AT solasswiebke pipacpressurizedintraperitonealaerosolchemotherapycancerunderpressure |